Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Daiichi Sankyo
Johnson and Johnson
Julphar
Fish and Richardson
Boehringer Ingelheim
Cerilliant
Chinese Patent Office
Teva

Generated: May 22, 2018

DrugPatentWatch Database Preview

CEDILANID-D Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Cedilanid-d patents expire, and what generic alternatives are available?

Cedilanid-d is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in CEDILANID-D is deslanoside. Additional details are available on the deslanoside profile page.
Summary for CEDILANID-D
Drug patent expirations by year for CEDILANID-D
Medical Subject Heading (MeSH) Categories for CEDILANID-D
Synonyms for CEDILANID-D
(3beta,5beta,12beta)-3-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide
11004-41-4
11029-69-9
1329-81-3
17598-65-1
3-[(O-beta-D-glucopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3beta,5beta,12beta-card-20(22)-enol
35-58-5
3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy-12beta,14-dihydroxy-5beta,14beta-card-20(22)-enolid
3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy=12beta.14=dihydroxy-5beta,14beta-card-20(22)-enolid
3beta-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12beta,14-dihydroxy-5beta-card-20(22)-enolide
4-18-00-02455 (Beilstein Handbook Reference)
598D651
8100AH
AC1L1FPG
Ambap17598-65-1
BRN 0078187
C47H74O19
CA006475
Card-20(22)-enolide, 3-((O-beta-D-glucopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,1
Card-20(22)-enolide, 3-((O-beta-D-glucopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12be
CAS-17598-65-1
Cedilanid D
Cedilanid-d (TN)
Cedilanide
CHEBI:31468
CHEMBL1614
D01240
D07TGN
DB01078
Deacetylanatoside C
Deacetyllanatoside C
Desace
Desacetyl Lanatoside
Desacetyl-Lanatoside C
Desacetyldigilanide C
Desacetyllanatoside C
Deslanatoside C
deslanoside
Deslanoside (JP15/USP/INN)
Deslanoside (JP17/USP/INN)
Deslanoside [USAN:BAN:INN:JAN]
Deslanoside C
Deslanosido
Deslanosido [INN-Spanish]
Deslanosidum
Deslanosidum [INN-Latin]
Deslanosidum C
DSSTox_CID_2897
DSSTox_GSID_22897
DSSTox_RID_76778
DTXSID1022897
EINECS 241-568-1
glucodigoxin
GTPL6806
Lanatosid C
Lanatoside C, deacetyl-
Lekozid
LS-87553
MFCD00135818
NCGC00159441-02
NCGC00159441-03
OBATZBGFDSVCJD-LALPQLPRSA-N
Purpurea glycoside C
SCHEMBL125311
Sediranido
Tox21_111671
Tox21_111671_1
UNII-YGY317RK75
YGY317RK75
ZINC253668332

US Patents and Regulatory Information for CEDILANID-D

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis CEDILANID-D deslanoside INJECTABLE;INJECTION 009282-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Chinese Patent Office
McKesson
US Department of Justice
Healthtrust
McKinsey
US Army
Mallinckrodt
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.